The Impact of Probiotics on Gut Microbiota and Non-Alcoholic Fatty Liver Disease (NAFLD) Progression

The Impact of Probiotics on Gut Microbiota and Non-Alcoholic Fatty Liver Disease (NAFLD) Progression: Controlled Attenuated Parameter (CAP) Elastography Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202204591594284

Enrollment

Registered

2022-04-06

Start date

2018-10-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

NASH

group II

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with bright liver having steatosis detected by (VCTE-CAP) elastography

Exclusion criteria

Exclusion criteria: The exclusion criteria were patients with a history of significant alcohol consumption more than 30 g/day in men and > 20 g/day in women, patients with positive hepatitis B or C virus markers, and patients with hepatic focal lesions.

Design outcomes

Primary

Measure	Time frame
to evaluate the effect of probiotics on non-alcoholic fatty liver disease progression and the decrease in fibrosis and normalization of the enzymes	—

Secondary

Measure	Time frame
adverse effects of probiotics	—

Countries

Egypt

Contacts

Public ContactFryal Elkalla

professor

fryalelkalla@med.tanta.edu.eg0123456780

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026